PhRMA submits comments urging CMS to withdraw coverage proposal

In comments submitted this week, PhRMA urged the Centers for Medicare& Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the treatment of Alzheimer ’s disease. The proposed policy would set a dangerous precedent of CMS severely restricting patient access to FDA-approved medicines, putting in place barriers to treatment options for a devastating illness, especially for patients in underserved communities. We urge CMS to instead provide Medicar e patients with appropriate and timely access to Alzheimer’s disease treatments.

Source: The Catalyst - February 11, 2022 Category: Pharmaceuticals Tags: Research and Development Alzheimer's Health Insurance Medicare Policy Solutions Source Type: news